×
About 127,902 results

ALLMedicine™ Melanoma Center

Research & Reviews  59,677 results

Phase I-II open label multicenter study of palbociclib + vemurafenib in BRAFV600MUT met...
https://doi.org/10.1158/1078-0432.CCR-20-4050
Clinical Cancer Research : an Official Journal of the Ame... Louveau B, Resche-Rigon M et. al.

May 5th, 2021 - In BRAFV600MUT metastatic melanoma, cyclin-D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of CDK4 inhibitors. In this phase I-II study, we aimed to establish the maximum tolerated ...

Preclinical development and first in human study of KA2507, a selective and potent inhi...
https://doi.org/10.1158/1078-0432.CCR-21-0238
Clinical Cancer Research : an Official Journal of the Ame... Tsimberidou AM, Beer PA et. al.

May 5th, 2021 - Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor. KA2507 was characterized in HDAC b...

LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and trea...
https://doi.org/10.1038/s41388-021-01808-3
Oncogene Billing O, Holmgren Y et. al.

May 5th, 2021 - Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-negative regulator of receptor tyrosine kinase (RTK) signaling and a tumor suppressor in several cancers, but its involvement in melanoma is largely unexplored. Here, we aim t...

The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
https://doi.org/10.1186/s13046-021-01947-1 10.1136/bjophthalmol-2016-309034 10.18632/oncotarget.6614 10.1016/j.cell.2015.05.044 10.1038/modpathol.2013.138 10.1016/j.ophtha.2011.01.040 10.1001/archopht.119.5.670 10.2214/ajr.157.6.1950883 10.1634/theoncologist.2015-0522 10.2147/OPTH.S89591 10.1016/S0161-6420(91)32285-1 10.1002/cncr.11872 10.1002/cncr.28480 10.1002/cncr.29727 10.17925/OHR.2017.13.02.100 10.1007/s00262-011-1089-0 10.1186/s40425-019-0800-0 10.1016/S1470-2045(17)30251-6 10.1016/j.ophtha.2012.02.017 10.1158/1078-0432.CCR-15-2071 10.1038/bjc.2011.189 10.1002/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X 10.1167/iovs.10-5979 10.1016/j.humpath.2017.06.005 10.1158/1078-0432.CCR-15-2294 10.1016/j.ajo.2009.01.023 10.1093/annonc/mdz176 10.20517/2394-4722.2017.39 10.3389/fimmu.2020.579894 10.1016/j.ejca.2008.10.026 10.1016/j.humpath.2017.09.012 10.1038/cmi.2010.56 10.4161/21624011.2014.947169 10.1002/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R 10.1097/cmr.0000000000000701 10.1038/nrc3245 10.1038/s41586-019-1914-8 10.1167/iovs.11-9280 10.1016/S0140-6736(18)30789-X 10.1186/2051-1426-2-s3-p193 10.1186/1479-5876-12-s1-p11 10.1002/hep.21060 10.1158/0008-5472.CAN-18-1367 10.2217/imt-2018-0156 10.1002/cncr.30258 10.2217/imt-2017-0066
Journal of Experimental & Clinical Cancer Research : CR; Tosi A, Cappellesso R et. al.

May 5th, 2021 - Uveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years from diagnosis, with the liver as the most common site. Upon metastatization, life expec...

Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case...
https://doi.org/10.1186/s13256-021-02821-6 10.1097/PAP.0b013e318216b99b 10.1046/j.1442-2050.2000.00140.x 10.1016/S0016-5107(00)70397-X 10.1200/JCO.2016.67.9258 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G 10.1111/1759-7714.13034 10.1056/NEJMoa1709030 10.1158/1078-0432.CCR-13-0739 10.1016/j.ejca.2019.07.001 10.6004/jnccn.2019.0018 10.1056/NEJMoa1412082 10.2217/imt-2018-0011
Journal of Medical Case Reports; Ito S, Tachimori Y et. al.

May 5th, 2021 - Primary malignant melanoma of the esophagus is a rare and aggressive disease that tends to have a poor response to chemotherapies. Previous studies have indicated that currently available treatment for primary malignant melanoma of the esophagus i...

see more →

Guidelines  183 results

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice r...
https://doi.org/10.1007/s00520-020-05709-1
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Girotra M et. al.

Aug 28th, 2020 - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T ...

ESMO consensus conference recommendations on the management of metastatic melanoma: und...
https://doi.org/10.1016/j.annonc.2020.07.004
Annals of Oncology : Official Journal of the European Soc... Keilholz U, Ascierto PA et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ESMO consensus conference recommendations on the management of locoregional melanoma: u...
https://doi.org/10.1016/j.annonc.2020.07.005
Annals of Oncology : Official Journal of the European Soc... Michielin O, van Akkooi A et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ASCO20 Virtual Scientific Program Showcases the Latest Advances in Melanoma Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200224/full/
ASCO Daily News;

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a range of studies showcasing the latest advances and clinical breakthroughs in melanoma research.

see more →

Drugs  61 results see all →

Clinicaltrials.gov  63,643 results

Phase I-II open label multicenter study of palbociclib + vemurafenib in BRAFV600MUT met...
https://doi.org/10.1158/1078-0432.CCR-20-4050
Clinical Cancer Research : an Official Journal of the Ame... Louveau B, Resche-Rigon M et. al.

May 5th, 2021 - In BRAFV600MUT metastatic melanoma, cyclin-D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of CDK4 inhibitors. In this phase I-II study, we aimed to establish the maximum tolerated ...

Preclinical development and first in human study of KA2507, a selective and potent inhi...
https://doi.org/10.1158/1078-0432.CCR-21-0238
Clinical Cancer Research : an Official Journal of the Ame... Tsimberidou AM, Beer PA et. al.

May 5th, 2021 - Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor. KA2507 was characterized in HDAC b...

LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and trea...
https://doi.org/10.1038/s41388-021-01808-3
Oncogene Billing O, Holmgren Y et. al.

May 5th, 2021 - Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-negative regulator of receptor tyrosine kinase (RTK) signaling and a tumor suppressor in several cancers, but its involvement in melanoma is largely unexplored. Here, we aim t...

The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
https://doi.org/10.1186/s13046-021-01947-1 10.1136/bjophthalmol-2016-309034 10.18632/oncotarget.6614 10.1016/j.cell.2015.05.044 10.1038/modpathol.2013.138 10.1016/j.ophtha.2011.01.040 10.1001/archopht.119.5.670 10.2214/ajr.157.6.1950883 10.1634/theoncologist.2015-0522 10.2147/OPTH.S89591 10.1016/S0161-6420(91)32285-1 10.1002/cncr.11872 10.1002/cncr.28480 10.1002/cncr.29727 10.17925/OHR.2017.13.02.100 10.1007/s00262-011-1089-0 10.1186/s40425-019-0800-0 10.1016/S1470-2045(17)30251-6 10.1016/j.ophtha.2012.02.017 10.1158/1078-0432.CCR-15-2071 10.1038/bjc.2011.189 10.1002/1097-0142(19900101)65:1<112::AID-CNCR2820650123>3.0.CO;2-X 10.1167/iovs.10-5979 10.1016/j.humpath.2017.06.005 10.1158/1078-0432.CCR-15-2294 10.1016/j.ajo.2009.01.023 10.1093/annonc/mdz176 10.20517/2394-4722.2017.39 10.3389/fimmu.2020.579894 10.1016/j.ejca.2008.10.026 10.1016/j.humpath.2017.09.012 10.1038/cmi.2010.56 10.4161/21624011.2014.947169 10.1002/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R 10.1097/cmr.0000000000000701 10.1038/nrc3245 10.1038/s41586-019-1914-8 10.1167/iovs.11-9280 10.1016/S0140-6736(18)30789-X 10.1186/2051-1426-2-s3-p193 10.1186/1479-5876-12-s1-p11 10.1002/hep.21060 10.1158/0008-5472.CAN-18-1367 10.2217/imt-2018-0156 10.1002/cncr.30258 10.2217/imt-2017-0066
Journal of Experimental & Clinical Cancer Research : CR; Tosi A, Cappellesso R et. al.

May 5th, 2021 - Uveal melanoma (UM) represents the most common primary intra-ocular malignancy in adults. Up to 50% of the patients develop distant metastases within 10 years from diagnosis, with the liver as the most common site. Upon metastatization, life expec...

Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case...
https://doi.org/10.1186/s13256-021-02821-6 10.1097/PAP.0b013e318216b99b 10.1046/j.1442-2050.2000.00140.x 10.1016/S0016-5107(00)70397-X 10.1200/JCO.2016.67.9258 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G 10.1111/1759-7714.13034 10.1056/NEJMoa1709030 10.1158/1078-0432.CCR-13-0739 10.1016/j.ejca.2019.07.001 10.6004/jnccn.2019.0018 10.1056/NEJMoa1412082 10.2217/imt-2018-0011
Journal of Medical Case Reports; Ito S, Tachimori Y et. al.

May 5th, 2021 - Primary malignant melanoma of the esophagus is a rare and aggressive disease that tends to have a poor response to chemotherapies. Previous studies have indicated that currently available treatment for primary malignant melanoma of the esophagus i...

see more →

News  4,237 results

Checkpoint Inhibitor Skin Side Effects More Common in Women
https://www.medscape.com/viewarticle/950535

May 4th, 2021 - Women had about a twofold higher risk than men of developing dermatologic adverse events while taking immune checkpoint inhibitors for metastatic melanoma in a review of 235 patients at Dana Farber Cancer Center, Boston, Massachusetts. Overall, 62...

Ellie Guardino, MD, Battled Others' Cancer but Has Lost to Her Own
https://www.medscape.com/viewarticle/949922

Apr 25th, 2021 - The oncology community is mourning the loss of Ellie Guardino, MD, PhD, a compassionate physician-scientist who fought through her own diagnosis of metastatic melanoma while contributing to important advances in breast cancer treatment. Dr Ellie G...

Teen Tanning Bed Ban Would Prevent More Than 15,000 Melanoma Cases
https://www.medscape.com/viewarticle/949666

Apr 20th, 2021 - A ban on the use of tanning beds by minors aged 14-17 years in the United States would prevent over 15,000 cases of melanoma and cost less than other, well-established public health interventions, according to a microsimulation of that age group's...

Surveillance, Education May Help to Catch Melanomas Earlier
https://www.medscape.com/viewarticle/949439

Apr 18th, 2021 - NEW YORK (Reuters Health) - A longitudinal surveillance program that included skin-cancer screening and education about self-exams was associated with significantly thinner and earlier-stage melanomas at diagnosis in members of melanoma-prone fami...

Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
https://www.medscape.com/viewarticle/949413

Apr 15th, 2021 - First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial. Tebentafusp is the first investigational therapy in a phase 3 trial...

see more →

Patient Education  101 results see all →